EGFR and cancer: MiR-193a, one of the candidate miRNAs in BRAF-mutated cells, acts as a tumor suppressor by regulating multiple cancer-related genes and affects cellular sensitivity to MAPK-related pathway inhibitors, such as BRAF inhibitors, MEK inhibitors, and, or anti-EGFR antibodies (Hiraide et al., 2021).